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Abstract: 
The HIV (human immuno-deficiency virus) integrase has a crucial role in viral replication. Moreover, it has no cellular 
homologue in humans. Hence, it is considered as an attractive drug target. Many inhibitors against the integrase protein has 
been designed and discussed. The Y-3 inhibitor (4-acetyl amino-5-hydroxy naphthalene - 2, 7- disulfonic acid) is already 
known to inhibit HIV-1 integrase. However, it is not suitable as a drug like candidate due to its high cyto-toxicity. In this 
report, a pharmacophore model for HIV integrase is described using the already known Y-3 inhibitor binding site. Fourteen 
compounds chemically related to the Y-3 inhibitor were generated using the described pharmacophore model and reported. 
Subsequent computational analysis showed that these compounds have interactions with the Y3 binding site and their 
possible utility as an integrase inhibitor is discussed.  
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Background: 
AIDS (acquired immuno-deficiency syndrome) is a major 
epidemic caused by HIV (human immuno-deficiency virus) 
and significant efforts are being made for years to develop 
drugs against the dreadful disease. The HIV genome 
encodes for the protease, reverse transcriptase and integrase 
enzymes. The HIV integrase contains three functional 
domains. [1] Interestingly, HIV
 integrase has no sequence 
homologue in the human host and hence, it is considered as 
a potential drug target. [2] The integrase protein has three 
domains, namely, the N-terminal domain stabilized by Zn
2+ 
[3, 4, 5], the DNA binding C-terminal domain [6] and the 
catalytic domain consisting of residues Asp64, Asp116, and 
Glu152 forming the active site. The catalytic triad is 
essential
 for enzymatic activity with metal cofactors. [4, 5] 
The structure of the C-terminal and N-terminal domains of 
the HIV-1 integrase were solved by NMR (nuclear 
magnetic resonance) [ 7,  8,  9],  whereas, the catalytic 
domain of HIV integrase was determined by x-ray 
crystallography.  [10,  11]  A number of natural products 
inhibiting integrase have been reported, recently. [12] The 
macromolecular crystallography laboratory identified three 
structurally related inhibitors called Y-1, Y-2 and Y-3. 
Among them, Y-3 (Figure 1) showed maximum integrase 
inhibition. [13] Y-3 interacts with the flexible loop of the 
enzyme’s active site and induces loop conformation 
change. Pre-incubation of integrase with metal
 cations did 
not prevent Y3 inhibition. [14] Pharmacophores describing 
interactions between integrase and ligands are important in 
drug screening. Inhibitors with high potency, solubility and 
reduced toxicity are generally considered for clinical trials. 
[13] Here, we describe the design of potential inhibitors for 
HIV integrase using a pharmacophore model. 
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Figure 1: Structure of the Y-3 inhibitor 
 
Methodology: 
Integrase catalytic domain structure 
The three dimensional structure of the catalytic domain of 
the HIV-1 integrase protein (PDB ID: 1BI4) was obtained 
from PDB (Protein Data Bank). [15] This domain consists 
of a five-stranded beta-sheet with six surrounding helices.  
 
Pharmacophore model 
We analyzed the binding pockets of the integrase catalytic 
domain using PASS (a tool that uses geometry to 
characterize regions of buried volume in proteins) to 
identify positions likely to represent binding sites based on 
size, shape and volume buried [16] (Figure 2). LigBuilder 
(a program for structure-based drug design) was used to 
build ligand molecules within the binding pocket of the Bioinformation by Biomedical Informatics Publishing Group    open access 
www.bioinformation.net   Hypothesis 
____________________________________________________________________________________________________________ 
ISSN 0973-2063 
Bioinformation 1(4): 112-117 (2006) 
Bioinformation, an open access forum 
© 2006 Biomedical Informatics Publishing Group 
 
113
HIV-1 integrase catalytic domain. [17] A pharmacophore 
model for receptor active site was derived using the 
POCKET module in LigBuilder. It should be noted that the 
previously proposed pharmacophore models were based on 
already known HIV-1 integrase inhibitors. [18, 19]  
 
 
Figure 2: Cavities predicted by PASS for HIV-1 
integrase 
 
Inhibitor design 
The 3D database searching methods that search for 
inhibitors in known compounds have been described 
elsewhere. [20, 21, 22] A dynamic pharmacophore model 
(screen a database of chemical compounds) for HIV-1 
integrase was also available. [23, 24, 25] Here, we describe 
a pharmacophore model using receptor active site and key 
interaction sites for Y-3 inhibitor as a seed compound. The 
model was used for constructing novel ligand molecules 
within the constraints of the target intergrase using the 
LigBuilder program. A total of 3000 ligand molecules were 
constructed using the GROW module in LigBuilder.  
 
Compounds generation 
An initial population was generated based on the seed 
structure and the parent molecules are copied into the 
mating pool. Thus, a new population was generated by 
performing structural manipulations to the molecules in the 
mating pool. The generated molecules were analyzed using 
the PROCESS module in LigBuilder. A set of 500 
molecules meeting the chemical criteria setup in the 
parameter file in PROCESS module were filtered and then 
converted into viewable Mol2 formatted files. LigBuilder 
estimates binding affinities using the SCORE v2.08 
algorithm  [26]  and LogP values using the XLOGP v2.0 
algorithm [27] for each compound. These 500 molecules 
were then clustered into 21 groups based on structural 
similarity. The compounds were then tested for Lipinski’s 
Rule of Five using the Molinspiration server. [28]  
 
Ligand binding 
The AutoDock3.0/ADT [29]  program was used to 
investigate ligand binding to HIV-1 integrase using a 
grid encompassing the active site surface. The AutoDock 
program combines a rapid energy evaluation through 
pre-calculated grids of affinity potentials with a variety 
of search algorithms to find suitable binding positions. 
The affinity and electrostatic maps were computed with a 
grid spacing of 0.375 Å and the grid points in x, y and z 
axis were set to 58x58x56. The search was based on the 
Lamarckian genetic algorithm and the results were 
analyzed using binding energy. The cluster analysis was 
performed based on RMSD (root mean square 
deviation). For each ligand, a docking experiment 
consisting of 10 simulations was performed. The ligand 
molecules were then ranked in order of increasing 
docking energies and grouped into clusters of similar 
conformation. The Swiss-PdbViewer was then used to 
generate images of protein structures docked with 
potential compounds.  
 
Results and Discussion: 
A static pharmacophore model was developed using 
LigBuilder based on the crystal structure of HIV-1 
integrase bound with the Y-3 inhibitor (4-acetylamino-5-
hydroxynaphthalene-2, 7-disulfonic acid). Figure 3 and 
Figure 4, shows the interaction between Y-3 inhibitor 
and active site residues Asp64, Asp116, Glu152 in the 
catalytic domain of integrase. In Figure 5, nitrogen atoms 
(blue) represent hydrogen-bond donor sites; oxygen 
atoms (red) represent hydrogen-bond acceptor sites; and 
carbon atoms (green) represent hydrophobic sites. Using 
the pharmacophore model, 500 out of the initial 3000 
molecules satisfying the minimum chemical criteria were 
identified for further analysis (Table 1). The 500 
compounds were then grouped in 21 different clusters 
using structural similarity. A molecule from each cluster 
was chosen based on binding affinity to integrase. 
Fourteen (structures given in Figure 7) of the twenty-one 
molecules satisfied the Lipinski's rule of five with zero 
violations (Table 2). A useful parameter for predicting 
drug transport properties is TPSA (Topological 
Molecular polar surface area) and it is determined for 
these molecules. A topological parameter is number of 
rotatable bonds and it describes the molecular flexibility 
of these compounds. This parameter was calculated for 
the fourteen molecules that satisfy the ‘rule-of-5’ and it 
is found that all the molecules have rotatable bonds in 
the range of 2-6 (Table 3).  
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Figure 3: Y3 inhibitor interacting with HIV-1 integrase 
 
 
Figure 4: Y3 inhibitor interacting with HIV-1 integrase  
 
All docking calculations were carried out using 
AutoDock3.0/ADT. Each of the fourteen molecules was 
docked into the active site of integrase that is fixed with 
flexible ligands. A smaller grid, concentrating on the 
catalytic domain of integrase was used for 10 
simulations. The docked conformation with the lowest 
free binding of energy was then probed for further 
analysis. The docking results revealed a consistent set of 
binding characteristics for the 14 molecules with HIV-1 
integrase (Figure 6). AutoDock calculated RMSD value, 
free energy and the docked energy values for the 
resulting fourteen structures (Table 4). Thus, we 
demonstrate the building of small-molecule inhibitors for 
HIV-1 integrase using a pharmacophore model.  
 
 
Figure 5: A pharmacophore model for integrase 
 
 
Figure 6: Docked complex between HIV-1 integrase 
and 14 generated molecules 
 
Maximal Molecular weight  500 
Minimal Molecular weight  50 
Maximal LogP  5.0 
Minimal LogP  -5.0 
Maximal PKD  5.0 
Minimal PKD  1.0 
Similarity cutoff  1.0 
Number of molecules satisfied the criteria  500 
Table 1: Chemical criteria used for PROCESS 
module in LigBuilder 
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Molecule  MiLogp  Mw  H acceptor  H donor  Violations 
Y-3 -0.719  359.337  9  2  0 
1 0.906  481.504  10  1  0 
2 1.131  493.515  10  0  0 
3 1.317  489.527  9  0  0 
4 -0.103  453.45 10  0  0 
5 -0.799  498.491  12  2  1 
6 1.196  489.527  9  0  0 
7 -0.188  465.461  10  0  0 
8 -0.374  496.475  12  1  1 
9 0.858  481.504  10  0  0 
10 0.979  455.466  10  0  0 
11 1.137  479.488  10  0  0 
12 -1.764  483.436 13  1  1 
13 0.293  467.477  10  0  0 
14 0.948  495.531  10  0  0 
15 -0.574  467.433 11  1  1 
16 -0.558  468.465 11  1  1 
17 1.324  481.504  10  0  0 
18 0.672  479.488  10  0  0 
19 -0.762  498.447 13  2  1 
20 -0.857  482.492 11  1  1 
21 1.136  489.483  10  0  0 
Table 2: Lipinski’s rule of five calculated by Molinspiration 
 
Molecule TPSA Atoms  Rotatable 
bonds 
Volume 
Y-3 151.752  23  3  257.413 
1 152.197  32  2 368.637 
2 141.203  33  4  385.03 
3 131.969  33  3 382.513 
4 149.04  30  3 340.148 
5 131.969  33  5 387.431 
6 149.04  31  2 350.387 
7 149.04  33  6 394.675 
8 149.04  33  4 371.617 
9 149.04  30  5 350.373 
10 149.04  32  5 372.242 
11 149.04  31  3 356.683 
12 149.04  32  4 373.402 
13 149.04  32  4 367.189 
14 149.04  32  6 378.428 
Table 3: Molecular properties for ligand molecules 
Molecule RMSD 
A 
Estimated 
free energy 
kcal/mol 
Final docked 
energy 
Kcal/mol 
1 0.360 -6.73  -7.94 
2 0.669 -8.10  -10.44 
3 0.361 -8.65  -7.51 
4 0.525 -6.96  -8.31 
5 0.815 -8.49  -10.33 
6 0.335 -7.46  -8.64 
7 0.565 -8.03  -10.20 
9 0.627 -6.35  -7.79 
10 0.417  -7.64  -10.05 
11 0.448  -7.56  -9.18 
12 0.524  -7.14  -7.77 
13 0.496  -7.28  -8.63 
14 0.551  -7.76  -9.81 
Table 4: Energy values from AutoDock 
 
 Bioinformation by Biomedical Informatics Publishing Group    open access 
www.bioinformation.net   Hypothesis 
____________________________________________________________________________________________________________ 
ISSN 0973-2063 
Bioinformation 1(4): 112-117 (2006) 
Bioinformation, an open access forum 
© 2006 Biomedical Informatics Publishing Group 
 
116
 
Figure 7: Two dimensional structures of fourteen ligand molecules 
 
Conclusion: 
The purpose of this study is to generate novel 
compounds as HIV-1 integrase inhibitors. A receptor 
based pharmacophore model was developed for HIV-1 
integrase with a variety of pharmacophore features 
(hydrogen-bond acceptor and donor, hydrophobic, and 
excluded volumes). In this study, fourteen molecules 
were identified as potential integrase inhibitors. Docking 
results from using AutoDock illustrated the molecular 
interactions between the 14 compounds and the HIV-1 
integrase. Further studies on their binding properties will 
provide useful information towards the rational design of 
effective HIV-1 integase inhibitors.  
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